Established drugs were repurposed, “me-too” drugs were approved, and even the few new biological approaches lacked clinical ...
Attention-deficit/hyperactivity disorder (ADHD), which causes affected individuals to be impulsive, hyperactive, or inattentive, is typically treated with medications ...
In November, the Boston-based biotech firm Karuna Therapeutics submitted its new schizophrenia medication, called KarXT, to the US Food and Drug Administration for approval. If the agency gives KarXT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results